

# Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)

To the Editor,

A recent report on “bone metastases treatment by samarium (sm)-153 oxabifore in combination with monoclonal antibody denosumab (Xgeva)” is very interesting.<sup>[1]</sup> Rasulovala *et al.* noted that “combined treatment of bone metastases with sm-153 oxabifore and denosumab is effective and safe.<sup>[1]</sup>” In fact, the combination is very interesting. A similar observation was also reported by Rasulovala *et al.* on another combination between sm-153 oxabifore and bisphosphonate. Focusing

on the present combination, sm-153 oxabifore and denosumab, the issue of side-effect should be studied in a larger scale. In fact, denosumab is generally used for management of bone loss in cancer patients.<sup>[2]</sup> However, some interesting side-effect of this drug can be seen. The important condition is osteonecrosis.<sup>[3,4]</sup> For sm-153, the effectiveness and side-effect is still inconclusive. The flare up of pain can be possible during therapy. As already note, further studies are still required for conclusion (see a clinical report in Russian language: base.ukgma.kz/vestnik/2012/vestnik\_3\_12.doc).

**Beuy Joob, Viroj Wiwanitkit<sup>1</sup>**

Department of Medical Center, Sanitation 1 Medical Academic Center, Bangkok, Thailand, <sup>1</sup>Tropical Medicine, Joseph Ayo Babalola University, Osun State, Nigeria

## References

1. Rasulovala N, Lyubshin V, Arybzhanov D, Krylov V, Khodjibekov M. Effectiveness of bone metastases treatment by sm-153 oxabifore in combination with monoclonal antibody denosumab (xgeva): First experience. *World J Nucl Med* 2013;12:19-23.
2. Rasulovala N, Lyubshin V, Arybzhanov D, Sagdullaev Sh, Krylov V, Khodjibekov M. Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease. *World J Nucl Med* 2013;12:14-8.
3. Yee AJ, Raje NS. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. *Clin Interv Aging* 2012;7:331-8.
4. Aghaloo TL, Dry SM, Mallya S, Tetradis S. Stage 0 osteonecrosis of the jaw in a patient on denosumab. *J Oral Maxillofac Surg* 2014;72:702-16.

### Access this article online

#### Quick Response Code:



#### Website:

www.wjnm.org

#### DOI:

10.4103/1450-1147.144825

#### Address for correspondence:

Dr. Beuy Joob, Sanitation 1 Medical Academic Center, Bangkok, Thailand. Email: beuyjoob@hotmail.com